Pradžia › Osteosarkoma › North Carolina
Osteosarkoma klinikiniai tyrimai North Carolina
6 tyrimai dėl Osteosarkoma ieško dalyvių vietose North Carolina.
Miestai North Carolina
Oficialus tyrimo tekstas (anglų kalba)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Duke University Medical Center, Durham
Renkami dalyviai2 fazė
Amžius nuo 12 iki 39 · Visoms lytims · Atnaujinta 2026-09-29 · NCT04616560The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Levine Children's Hospital, Charlotte
- Novant Health Hemby Children's Hospital, Charlotte
- ir dar 3
Renkami dalyviai2 fazė
Amžius nuo 7 iki 22 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07560826Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- ir dar 2
Renkami dalyviai3 fazė
Iki 50 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT05235165SPEARHEAD-3 Pediatric Study
- Duke University School of Medicine, Durham
Renkami dalyviai1/2 fazė
Amžius nuo 2 iki 21 · Visoms lytims · Atnaujinta 2026-08-11 · NCT05642455Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Mission Hospital, Asheville
- Wake Forest University Health Sciences, Winston-Salem
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-05-18 · NCT01790152Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Renkami dalyviai1 fazė
18 Months · Visoms lytims · Atnaujinta 2026-03-27 · NCT03721068Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.